Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.

Gilead’s Remdesivir AKA Velkury has emergency use authorization (EUA) n the United States and just barely reduces hospital length of stay in some patients and it is questionable if it really reduces mortality to any degree. It has NOT received FDA approval because it hasn’t performed in real life practice. As soon as the FDA sees another drug that can reduce length of stay and save some lives, Remdesivir will lose it’s EUA and it’s share of the market which is pretty much all of it.

Remdesivir needs Brilacidin, but it is abundantly clear that Brilacidin does not need Remdesivir. I anticipate the placebos will be whatever the standard of care is being used in the respective country as it is unethical to withhold treatment in a life or death situation. Brilacidin will go head to head vs. Remdesivir and we all know who will win.


Efftiabdunnsunnylemonturds!

MORE NAKED THAN a hairless cat!

Stock symbol: IPIX. Dam criminals have orchestrated various attempts to bankrupt this company who just may save the world.

The drug, Brilacidin, is a synthetic molecule developed by the University of Pennsylvania using a super computer that made nonstop calculations for 6.8 years before arriving at it. It is designed to be safe, antifungal, antiviral, antibacterial and anti-inflammatory. It is also designed to be easily incorporated into plastics and paint. It has already undergone 8 other human trials successfully and is about to start human trials for COVID-19. You still have time to build your position. Lots of room to grow.

Read these:

http://www.ipharminc.com/press-release/2021/1/14/innovation-pharmaceuticals-brilacidin-for-the-treatment-of-covid-19-receives-fda-fast-track-designation


http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

Can’t get more de-risked than this.

Stock symbol: IPIX.
The drug, Brilacidin, is a synthetic molecule developed by the University of Pennsylvania using a super computer that made nonstop calculations for 6.8 years before arriving at it. It is designed to be safe, antifungal, antiviral, antibacterial and anti-inflammatory. It is also designed to be easily incorporated into plastics and paint. It has already undergone 8 other human trials successfully and is about to start human trials for COVID-19. You still have time to build your position. Lots of room to grow.

Read these:

http://www.ipharminc.com/press-release/2021/1/14/innovation-pharmaceuticals-brilacidin-for-the-treatment-of-covid-19-receives-fda-fast-track-designation


http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

Can’t get more de-risked than this.

IPIX phase II study for Brilacidin given the green light to start WITHOUT Remdesivir. Gilead needs to buy a boarding pass or miss this flight.

No big deal. Certificates for Polio and Small Pox vaccination were commonly used in the past in MANY countries.

Looks like Gilead will lose some market share for Remdesivir. Perhaps this will finally prompt them to partner with Innovation Pharmaceuticals for Brilacidin.


https://www.cnbc.com/2020/11/19/coronavirus-who-tells-doctors-dont-use-gileads-remdesivir-splitting-with-fda.html?__source=androidappshare&fbclid=IwAR3z4fzJHQ1-U7LEK92Jfa-6ADdoY7GL8teKHO79HV9anxPyze-QCA5ghUU

We are not dogs prone to chase squirrels. This doesn’t change the findings for Remdesivir + Brilacidin.

I’m sorry but I’m not familiar with the credential your buddy holds. “Drug Designer” sounds important... possibly...

The studies highlighting Brilacidin’s effectiveness are coming from the highest bio containment government labs.

This is what will bring the pandemic to an end. A real cure. This partnership better hurry or IPIX will steal the stage and the limelight. Brilacidin is clearly more effective than Remdesivir as a stand-alone drug and in vivo testing just around the corner.

Remdesivir needs Brilacidin and not the other way around. Gilead can either be stomped out by the competition or join forces and dominate the market.

Boom! Gilead better partner up!


http://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2

https://www.reuters.com/article/us-gilead-sciences-results-idUSKBN27D2ZJ

Looks like Lilly will take a slice of the pie.


https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-us-government-supply-300000-vials?fbclid=IwAR0WDohiOBccubYR8nSAVNyiwK9mXBhA9P6N7ksHfIoVsQDHZNK7I2WEdMw

The bar is really low and better treatments are coming and the market is keenly aware.

The world knows Remdesivir doesn’t do much and will be replaced. May even lose their FDA approval.

2 weeks before the election the President is given something to gloat about. The bar is literally resting on the floor. There will be better therapeutic drugs and soon.

The bar is essentially on the floor. The magic of election years never ceases to amaze me.

Now that sounds like a cure.

Giving the President something to gloat about 2 weeks before election day should create a pop... Once the dust settles and the new pandemic day traders take their beer and pizza money out, it may even be sustained for a few weeks until something better comes along... Something better will come along, the bar is ridiculously low.

I don’t think the up-list will provide the movement you are expecting. However, some positive trial news will get this out of 1st gear.

Per the link: “But if we can learn anything from the mental gyrations required to square these conflicting study results, it’s that we definitely need more effective options”

***The bar isn’t set very high. More effective options will come. Will Remdesivir be part of the solution or fade away on the shelves??? My crystal ball never works but in this case I think it’s clear that Brilacidin will replace Remdesivir. Gilead better wrap up negotiations or be pushed aside.

Each country in Asia has their own version of the FDA. They are not like the European Union so they would still have to go through whatever process is prescribed by the countries involved. It could be as easy as saying, “Well US FDA approved it so we will too” or something much more time consuming and costly... who knows really.

Great advice. “Know what you own”... sage and timeless. I would just add that in business, any business, know what the competition is up to and has up their sleeve.

The bar is set ridiculously low right now and Remdesivir is the best we can do... for now. If Gilead misses the opportunity to partner or scoop up Brilacidin, not only will they be pushed out of the Covid arena, they may also become irrelevant as a manufacturer of antivirals.

It’s got EUA but early on in the pandemic the bar was set pretty low. Now that real numbers from proper studies are coming in no one is impressed. Gilead has built a reputation/brand on fighting viruses and now that brand will have a big black eye going forward. They should partner with that innovative pharmaceutical company to save face and save the world.

Now that’s impressive. Should be worth multiples of what a current dose of Remdesivir is going for now. VERY INNOVATIVE indeed.

Time to buy up some small pharmaceutical companies with strong potential. Gilead is about to lose the horse race but can still win by buying or partnering with “innovative” companies.

Very nice

Crystal ball must be broken

You forgot IP!X.

Good read, thank you. Impressive and it looks like the drug can be delivered via IV to facilitate treating the hospitalized patients and orally for those that are not hospitalized. If successful it could be widely prescribed.

I agree wholeheartedly. We need a treatment to get out of this mess. I just think that it is not a one horse race and the way things play out in the long run will depend on many variables... too many to think the race has already been won. I am cheering for a cure and one to come sooner rather than later. RLF-100 may be it... or maybe.

It doesn’t matter if your horse is the first out the gate. What matters is wether or not your Jockey gets the flowers and a kiss from a beautiful girl at the end.

I see a trifecta is possible... place your bet.

This change should result in a shorter trial by not having to wait for the follow up.

Did they mention trials in Europe prior to this PR? Very optimistic.

Plasma was pushed because he needed something to brag about during the RNC this week. RLF will be pushed by the Dr.s as the results come trickling out.

I haven’t read the link but the post suggests to me that a BARDA grant has been requested. A grant would not have to be paid back and is a significant vote of confidence on behalf of the government.

It is their race to lose and losing it they are. In the meantime they will make a pretty penny charging thousands to possibly, barely, help a few.

...almost criminal really.

The race to cure Covid-19 is a three horse race right now. (R, R and I)

(With Remdesivir still around to kick up dirt)

***they will all have major stock moves at this point and they are all likely to have some success.

BUT in the end, it will not be the company that breaksout 1st that makes the most money, it will be the one with the best drug and that is hands down I??X

Who is setting up the suicide watch for the shorties?